BRIEF—Celonic acquires Glycotope's bio-manufacturing facility

Celonic, a Swiss global biologics development and manufacturing services provider, and Berlin-based Glycotope, a clinical stage immune-oncology company, today announced the successful completion of Celonic’s acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany.

Financial terms of the deal were not disclosed,

The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in strategic assets and innovative technology platforms.

The acquisition is expected to accelerate top-line growth, driven by expanded GMP manufacturing assets and by an immediate investment in capacity for late-stage and commercial supply.

Dr Konstantin Matentzoglu, Celonic's chief executive, said: "With on-boarding of almost two decades of invaluable experience in optimization of perfusion continuous manufacturing processes, Celonic is well positioned to offer our customers the flexibility and the advantages of perfusion and fed-batch manufacturing – from pilot to commercial scale.”

“Also, adding Glycotope’s highly complementary GEX human cell line platform to Celonic’s innovative CHOvolution integrated development platform gives our pharmaceutical and biotech customers the unique opportunity to select a tailored expression system, suitable for their bio-therapeutics development needs,” Dr Matentzoglu added.